Arata Corporation (TYO:2733)
Japan · Delayed Price · Currency is JPY 3,215.00
+65.00 (2.06%)
Aug 8, 2025, 3:30 PM JST
Verve Therapeutics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 991,800 | 986,212 | 944,149 | 891,600 | 857,087 | 834,033 | Upgrade | |
Revenue Growth (YoY) | 3.91% | 4.46% | 5.89% | 4.03% | 2.76% | 4.75% | Upgrade |
Cost of Revenue | 895,397 | 889,991 | 851,730 | 804,794 | 772,646 | 748,325 | Upgrade |
Gross Profit | 96,403 | 96,221 | 92,419 | 86,806 | 84,441 | 85,708 | Upgrade |
Selling, General & Admin | 82,051 | 81,224 | 77,901 | 73,960 | 71,697 | 74,020 | Upgrade |
Operating Expenses | 82,056 | 81,229 | 77,909 | 73,990 | 71,693 | 74,185 | Upgrade |
Operating Income | 14,347 | 14,992 | 14,510 | 12,816 | 12,748 | 11,523 | Upgrade |
Interest Expense | -476 | -429 | -288 | -170 | -169 | -174 | Upgrade |
Interest & Investment Income | 263 | 246 | 224 | 211 | 185 | 165 | Upgrade |
Earnings From Equity Investments | 1 | -9 | -112 | -17 | 4 | -2 | Upgrade |
Other Non Operating Income (Expenses) | 483 | 628 | 828 | 675 | 841 | 482 | Upgrade |
EBT Excluding Unusual Items | 14,523 | 15,428 | 15,162 | 13,515 | 13,609 | 11,994 | Upgrade |
Gain (Loss) on Sale of Investments | 9 | 9 | 81 | -641 | -9 | 87 | Upgrade |
Gain (Loss) on Sale of Assets | 156 | 212 | 116 | 164 | 142 | 148 | Upgrade |
Asset Writedown | -21 | -23 | -175 | -100 | -226 | -67 | Upgrade |
Other Unusual Items | -1 | -1 | -1 | -9 | -257 | 1 | Upgrade |
Pretax Income | 14,666 | 15,625 | 15,183 | 12,929 | 13,259 | 12,163 | Upgrade |
Income Tax Expense | 4,950 | 5,258 | 4,844 | 4,703 | 4,247 | 3,970 | Upgrade |
Earnings From Continuing Operations | 9,716 | 10,367 | 10,339 | 8,226 | 9,012 | 8,193 | Upgrade |
Minority Interest in Earnings | -4 | -9 | -17 | -3 | -3 | 7 | Upgrade |
Net Income | 9,712 | 10,358 | 10,322 | 8,223 | 9,009 | 8,200 | Upgrade |
Net Income to Common | 9,712 | 10,358 | 10,322 | 8,223 | 9,009 | 8,200 | Upgrade |
Net Income Growth | -8.12% | 0.35% | 25.53% | -8.72% | 9.87% | 14.03% | Upgrade |
Shares Outstanding (Basic) | 33 | 33 | 34 | 34 | 34 | 34 | Upgrade |
Shares Outstanding (Diluted) | 33 | 33 | 35 | 36 | 36 | 36 | Upgrade |
Shares Change (YoY) | -1.68% | -3.33% | -3.82% | - | 0.07% | -2.15% | Upgrade |
EPS (Basic) | 290.57 | 309.53 | 303.01 | 240.78 | 263.79 | 240.29 | Upgrade |
EPS (Diluted) | 290.57 | 309.53 | 298.19 | 228.49 | 250.34 | 228.00 | Upgrade |
EPS Growth | -6.50% | 3.80% | 30.51% | -8.73% | 9.80% | 16.54% | Upgrade |
Free Cash Flow | - | 5,294 | 10,514 | 8,607 | 1,665 | 10,060 | Upgrade |
Free Cash Flow Per Share | - | 158.20 | 303.72 | 239.15 | 46.26 | 279.71 | Upgrade |
Dividend Per Share | 102.000 | 102.000 | 92.500 | 68.000 | 58.000 | 47.500 | Upgrade |
Dividend Growth | 10.27% | 10.27% | 36.03% | 17.24% | 22.11% | 11.77% | Upgrade |
Gross Margin | - | 9.76% | 9.79% | 9.74% | 9.85% | 10.28% | Upgrade |
Operating Margin | 1.45% | 1.52% | 1.54% | 1.44% | 1.49% | 1.38% | Upgrade |
Profit Margin | 0.98% | 1.05% | 1.09% | 0.92% | 1.05% | 0.98% | Upgrade |
Free Cash Flow Margin | - | 0.54% | 1.11% | 0.97% | 0.19% | 1.21% | Upgrade |
EBITDA | 19,155 | 19,760 | 19,120 | 17,420 | 17,270 | 15,820 | Upgrade |
EBITDA Margin | - | 2.00% | 2.02% | 1.95% | 2.02% | 1.90% | Upgrade |
D&A For EBITDA | 4,808 | 4,768 | 4,610 | 4,604 | 4,522 | 4,297 | Upgrade |
EBIT | 14,347 | 14,992 | 14,510 | 12,816 | 12,748 | 11,523 | Upgrade |
EBIT Margin | - | 1.52% | 1.54% | 1.44% | 1.49% | 1.38% | Upgrade |
Effective Tax Rate | - | 33.65% | 31.90% | 36.38% | 32.03% | 32.64% | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.